Literature DB >> 21962523

Synthesis, biological evaluation, and molecular docking studies of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan moiety as potential anticancer agents.

Xiao-Min Zhang1, Min Qiu, Juan Sun, Yan-Bin Zhang, Yu-Shun Yang, Xiao-Liang Wang, Jian-Feng Tang, Hai-Liang Zhu.   

Abstract

In present study, a series of new 1,3,4-oxadiazole derivatives containing 1,4-benzodioxan moiety (6a-6s) as potential telomerase inhibitors were synthesized. The bioassay tests demonstrated that compounds 6k, 6l, 6m, 6n and 6s exhibited broad-spectrum antitumor activity with IC(50) concentration range from 7.21 μM to 25.87 μM against the four cancer cell lines, HEPG2, HELA, SW1116 and BGC823. Moreover, all the title compounds were assayed for telomerase inhibition using the TRAP-PCR-ELISA assay. The results showed compound 6k possessed the most potent telomerase activity (IC(50)=1.27 ± 0.05 μM). Docking simulation was performed to position compound 6k into the active site of telomerase (3DU6) to determine the probable binding model.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21962523     DOI: 10.1016/j.bmc.2011.08.013

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  12 in total

1.  Triterpenoids from Ganoderma lucidum inhibit the activation of EBV antigens as telomerase inhibitors.

Authors:  Dong-Shu Zheng; Liang-Shu Chen
Journal:  Exp Ther Med       Date:  2017-08-03       Impact factor: 2.447

Review 2.  The Development of FAK Inhibitors: A Five-Year Update.

Authors:  Andrea Spallarossa; Bruno Tasso; Eleonora Russo; Carla Villa; Chiara Brullo
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

3.  Synthesis and cytotoxic evaluation of some quinazolinone- 5-(4-chlorophenyl) 1, 3, 4-oxadiazole conjugates.

Authors:  Farshid Hassanzadeh; Hojjat Sadeghi-Aliabadi; Elham Jafari; Azadeh Sharifzadeh; Nasim Dana
Journal:  Res Pharm Sci       Date:  2019-10-04

4.  2,9-Bis(5-sulfanylidene-4,5-di-hydro-1,3,4-oxa-diazol-2-yl)-1,10-phenanthroline dimethyl sulfoxide disolvate.

Authors:  Md A Rahman; Mohammad Karim; Md Arifuzzaman; Tasneem Siddiquee; Lee M Daniels
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-02-22

5.  Synthesis, molecular modeling and anticancer activity of new coumarin containing compounds.

Authors:  Shaimaa A Morsy; Abdelbasset A Farahat; Magda N A Nasr; Atif S Tantawy
Journal:  Saudi Pharm J       Date:  2017-02-10       Impact factor: 4.330

6.  Synthesis, telomerase inhibitory and anticancer activity of new 2-phenyl-4H-chromone derivatives containing 1,3,4-oxadiazole moiety.

Authors:  Xu Han; Yun Long Yu; Duo Ma; Zhao Yan Zhang; Xin Hua Liu
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

7.  Synthesis and Anticancer Evaluation of New 1,3,4-Oxadiazole Derivatives.

Authors:  Camelia Elena Stecoza; George Mihai Nitulescu; Constantin Draghici; Miron Teodor Caproiu; Octavian Tudorel Olaru; Marinela Bostan; Mirela Mihaila
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-06

8.  Crystal structure and Hirshfeld surface analysis of 1-(4-chloro-phen-yl)-2-{[5-(4-chloro-phen-yl)-1,3,4-oxa-diazol-2-yl]sulfan-yl}ethanone.

Authors:  Rajesh Kumar; Shafqat Hussain; Khalid M Khan; Shahnaz Perveen; Sammer Yousuf
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2017-03-17

Review 9.  Synthetic approaches and pharmacological activity of 1,3,4-oxadiazoles: a review of the literature from 2000-2012.

Authors:  Cledualdo Soares de Oliveira; Bruno Freitas Lira; José Maria Barbosa-Filho; Jorge Gonçalo Fernandez Lorenzo; Petrônio Filgueiras de Athayde-Filho
Journal:  Molecules       Date:  2012-08-27       Impact factor: 4.411

Review 10.  Groundbreaking Anticancer Activity of Highly Diversified Oxadiazole Scaffolds.

Authors:  Alessandra Benassi; Filippo Doria; Valentina Pirota
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.